Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study

Scand J Gastroenterol. 1999 Jun;34(6):566-74. doi: 10.1080/003655299750026010.


Background: The impact of response to treatment on subsequent symptoms, quality of life, health care consumption, and absence from work in functional dyspepsia is unknown.

Methods: Patients with functional dyspepsia from Denmark, France, Germany, The Netherlands, Hungary, and Poland (n = 567 (215 men), 18-80 years old) were followed up for 3 months after a 4-week treatment trial with omeprazole (20 mg or 10 mg) or placebo. The patients were blinded to the initial treatment. Dyspeptic symptoms and quality of life were assessed, and dyspepsia-related costs were calculated in terms of number of clinic visits, days on medication, and absence from work.

Results: Responders had fewer clinic visits than non-responders (1.5 versus 2.0 mean visits) and fewer days on medication (mean, 9 days versus 23 days) over the 3-month period (both, P < 0.001). The quality of life in responders was better at study entry and persisted over 3 months (all, P < 0.001). When analysed country by country, health care costs due to clinic visits and medications were significantly lower in responders in all countries (P < 0.05), except Denmark and The Netherlands.

Conclusion: Symptom resolution in patients with functional dyspepsia has a positive impact on quality of life and reduces the subsequent costs over a 3-month period after cessation of initial treatment.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absenteeism
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Ambulatory Care / economics
  • Animals
  • Anti-Ulcer Agents / therapeutic use*
  • Delivery of Health Care / economics
  • Delivery of Health Care / statistics & numerical data*
  • Dyspepsia / drug therapy
  • Dyspepsia / economics*
  • Europe
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Prospective Studies
  • Quality of Life*
  • Recurrence
  • Treatment Outcome


  • Anti-Ulcer Agents
  • Omeprazole